Abstract T MP48: Androgen suppression in patients with prostate cancer increases incidence of combined cardiovascular outcomes

Authors

Zuber Ali, Advocate Aurora HealthFollow
Danielle M. Greer, Advocate Aurora HealthFollow
Robyn Shearer, Advocate Aurora HealthFollow
Syed Gardezi, Advocate Aurora HealthFollow
Arshad Jahangir, Sheikh Khalifa bin Hamad Al Thani Center for Integrative Research on Cardiovascular Aging, Aurora Research Institute, Advocate Aurora HealthFollow

Recommended Citation

Abstract T MP48: Androgen suppression in patients with prostate cancer increases incidence of combined cardiovascular outcomes. Stroke. 2015;46(Suppl 1):ATMP48.

Affiliations

Internal Medicine, Endocrinology, Cardiology

Abstract

Introduction: Androgen suppression therapy for prostate cancer is controversial due to adverse fatal and non-fatal cardiovascular outcomes reported in some studies. However, effects of androgen suppression on stroke have not been fully assessed in the elderly.

Methods: Patients diagnosed with prostate cancer during 2007-2013 in a large community-based healthcare system were identified from the Cancer Registry, electronic records, and billing codes. Those who underwent androgen suppression therapy with Gonadotropin-releasing hormone agonist (GnRH) were propensity-matched to patients treated without androgen suppression therapy by age at cancer diagnosis, race/ethnicity, disease stage and outcome, body mass index and use of surgery, radiation, and chemotherapy. Tests of independence and Cox proportional hazards models were used to examine effects of hormone therapy on acute myocardial infarction (AMI), stroke, and mortality outcomes. Models also adjusted for patient comorbidities.

Results: A total of 1282 patients and 641 matched-pairs were identified, with mean diagnosis age of 69 yr and follow-up period of 3.05 yr. Effects of androgen suppression therapy on AMI (P=0.051) and stroke (P=0.062) were of marginal to non-significance, but adjusted-odds of death and combined AMI, stroke, and death were 1.61 times (P=0.002; odds ratio [OR] 95% CI: 1.19-2.18) and 1.70 times (P74 yr) was discovered for combined outcomes, suggesting increased probability of AMI, stroke, and/or death with age (8.6-20.0%; P=0.003) for patients without androgen suppression but elevated risk of outcomes across all age groups (18.3-22.4%; P=0.546) for men treated with androgen suppression therapy.

Conclusion: Endogenous androgen suppression presents elevated risk of combined cardiovascular and death outcomes, especially for menyr.

Document Type

Abstract